Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 10, 2025Frontiers in OncologyOpen Access

Multiomics analyses of human colorectal cancer reveal changes in mitochondrial metabolism associated with chemotherapy resistance

View Full Paper
Ask AI
Bookmark
Share

Authors

SCShiyi ChenQLQian LiWZWei Zheng

Discussion

Loading...

Member takes

Overview

Multiomics analyses demonstrate altered mitochondrial metabolism in colorectal cancer linked to doxorubicin resistance, highlighting potential targets for therapy.

Key Points

  • This research aims to investigate mitochondrial metabolic changes associated with chemotherapy resistance in colorectal cancer.
  • Generated a chemotherapy-resistant colorectal cancer cell line, HCT-15/DOX, via doxorubicin induction.
  • Performed proteomic and metabolomic analyses using LC-MS/MS technology on cell lines.
  • Conducted transmission electron microscopy to examine mitochondrial morphology changes.
  • Identified significant dysregulation of 185 proteins and 1099 metabolites in HCT-15/DOX cells compared to parental cells.
  • Notable key functional proteins included upregulated SDHA and downregulated CRAT among others.
  • Associated metabolic pathways include pyrimidine metabolism and purine metabolism, linked to chemotherapy resistance.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/69253a1ec0ce034ddc356fcdhttps://doi.org/10.3389/fonc.2025.1625797
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mitochondrial metabolism is a key determinant of chemotherapy sensitivity in Colorectal Cancer2024 · 4 citations
  2. 2Mitochondrial metabolism determines chemotherapy sensitivity in colorectal cancer2026 · 2 citations
  3. 3Mitochondrial metabolic reprogramming in colorectal cancer: mechanisms of resistance and future clinical interventions2025 · 40 citations
  4. 4Abstract 4708: Metabolomics signatures with multidrug-resistant colorectal cancer cells2026
  5. 5Targeting the epigenome and tumor heterogeneity: advances in immunotherapy for chemoresistant metastatic colorectal cancer2025